Calciphylaxis Treatment Market is Expected to Gain Popularity Across the Globe by 2026 Analysis by Global Key Players 3M, Amgen Inc., BSN Medical, ConvaTec Inc., Medtronic Plc., Smith & Nephew Plc., and Laboratoris Sanifit S.L.

Calciphylaxis or Calcific Uremic Arteriolopathy (CUA) is the most severe form of cardiovascular calcification in dialysis patients. It starts with a calcification of small peripheral vessels and quickly spreads in the body. Moreover, people suffering from calciphylaxis have an imbalance in calcium metabolism, which causes calcium to be deposited in arterioles, which eventually leads to the formation of blood clots in the arterioles. Blood clots can cause fat tissues and skin to be deprived of oxygen and nourishment.

According to a data published by National Center for Biotechnology Information (NCBI) 2014 report, calciphylaxis affects around 4% of patients in the late stage of chronic kidney disease and 55% of patients with calciphylaxis die within a year of diagnosis and suffer from painful skin ulcers and a high risk of infection. No effective treatment for calciphylaxis is currently available and its causes are unknown. However, patients suffering from this disease are usually treated with intensive care, including wound management. The occurrence of calciphylaxis is associated with hyperthyroidism.

Download PDF Brochure of Market Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2251

Market Dynamics:

High prevalence of kidney diseases and increasing number of clinical trials in the field of calciphylaxis treatment are major factors expected to drive growth of the calciphylaxis treatment market. According to the National Institute of Diabetes and Digestive and Kidney Diseases Health Information Center, in 2016, the overall prevalence of chronic kidney diseases in the U.S. was around 14% of total population.

Calciphylaxis has no approved treatment, which has led to increasing number of clinical trials and research, which is expected to fuel growth of the market. For instance, in March 2015, the Multidisciplinary Calciphylaxis Program launched the first randomized trial for treatment of calciphylaxis with research focus on the role of vitamin K in the treatment of the disease.

Lack of an appropriate treatment for calciphylaxis is a major obstacle in the calciphylaxis treatment market growth. However, key players in the market are focused on identifying the root cause of the disease and its associated treatment in order to gain market share. For instance, according to a study published by the American Journal of Nephrology, in June 2018, apixaban, an anticoagulant used to treat venous thromboembolic events, can be a safe and effective alternative to warfarin in patients with End-Stage Renal Disease (ESRD) on dialysis suffering from calciphylaxis.

Calciphylaxis Treatment Market - Competitive Landscape

Key players operating in the global calciphylaxis treatment market include, 3M, Amgen Inc., BSN Medical, ConvaTec Inc., Medtronic Plc., Smith & Nephew Plc., and Laboratoris Sanifit S.L.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/2251

Detailed Segmentation:

• Global Calciphylaxis Treatment Market, By Treatment:
- Drug Therapy
- Hyperbaric Oxygen Therapy

• Global Calciphylaxis Treatment Market, By End User:
- Hospital and Clinics
- Homecare
- Ambulatory Centers

• Global Calciphylaxis Treatment Market, By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.